Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
by Zacks Equity Research
Clovis Oncology, NiSource, DocuSign, Root and Endava are part of the Zacks Screen of the Week article.
Bet on 5 Top Stocks With Rising P/E
by Sanghamitra Saha
Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
by Zacks Equity Research
Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.
Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
by Zacks Equity Research
Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
by Zacks Equity Research
Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing
by Zacks Equity Research
Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
by Zacks Equity Research
Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
by Zacks Equity Research
Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.
Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results
by Zacks Equity Research
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?